Obesity and periodontitis

Yıl 2012, Cilt: 2 Sayı: 2, 89 - 100, 31.01.2014

Oğuz Köse , Varol Çanakçı Taner Arabacı Ebru Sağlam

Öz

Obesity is defined as abnormal or excessive fat accumulation that may impair health. The basic cause of obesity and overweight is the disarrangement between the energy spent on physical activities and metabolism and quantity of the energy gained by the way of nutrition. Overweight and obesity prevalence reached to significant rates in developing and developed countries on various regions of the world. Obesity is regarded as a basic risk factor especially for type 2 diabetes, hypertension, cardiovascular system diseases and many other chronic inflammatory diseases and evolution of cancer. Although the biological mechanisms that betray the relation between obesity and periodental diseases haven’t been totally illustrated, it’s thought that the adipose tissue derived cytokines and hormones may have an important role. These hormones and cytokines may assist pathogenesis of the other chronic inflammatory diseases by causing hyperinflammatory response. In recent years, many studies were carried out in order to explain the relationship between obesity and periodontal diseases. Aim of this compilation is to analyze the relationship between obesity and periodontitis under the illustration of actual information.

Key words: Obesity, overweight, periodontitis, inflammation

Anahtar Kelimeler

-

Obezite ve periodontitis

Öz

Obezite vücut sağlığını bozacak ölçüde yağ dokusundaki anormal veya aşırı yağ birikmesidir. Obezitenin ve aşırı kilonun temel nedeni diyetle alınan enerji miktarı ile metabolizma ve fiziksel aktiviteler sırasında harcanan enerji miktarı arasındaki düzensizliktir. Aşırı kilo ve obezite prevalansı, dünyanın çeşitli bölgelerindeki gelişmiş ve gelişmekte olan ülkelerde ciddiyetle dikkate alınması gereken oranlara ulaşmıştır. Obezite başta tip 2 diyabet, hipertansiyon ve kardiyovasküler sistem hastalıkları olmak üzere pek çok kronik iltihabi hastalık ve kanser gelişimi için temel bir risk faktörü olarak kabul edilmektedir. Son dönemdeki çalışmalar obezitenin ağız hastalıkları, özellikle de periodontitis ile ilişkili olduğunu göstermiştir. Obezite ve periodontal hastalıklar arasındaki ilişkiyi ortaya koyan biyolojik mekanizmalar tam olarak aydınlatılamamışsa da, yağ doku kaynaklı sitokin ve hormonların anahtar role sahip olabilecekleri düşünülmektedir. Bu hormon ve sitokinler aşırı iltihabi cevaba neden olarak periodontitis ve diğer kronik enflamatuar hastalıkların patogenezine katkı sağlayabilir. Son yıllarda obezite ile periodontal hastalıklar arasındaki ilişkiyi açıklamaya yönelik pek çok çalışma yapılmıştır. Bu derlemenin amacı güncel çalışmalar ışığında obezite periodontitis ilişkisini incelemektir.

Anahtar Kelimeler : Obezite, aşırı kilo, periodontitis, enflamasyon

Anahtar Kelimeler

Obezite, aşırı kilo, periodontitis, enflamasyon

Kaynakça

• Meron Selassie BA, Sinha AC., MD. The epidemiology and aetiology of obesity: A global Challenge. Best Pract Res Clin Anaesthesiol. 2011;25: 1-9.
• World Health Organization. Obesity. Available at:http://www.who. int/topics/obesity/en/
• Kopelman PG. Obesity as a medical problem. Nature. 2000;404: 635- 643.
• Doll S, Paccaud F, Bovet P, Burnier M, Wietlisbach V. Body mass index, abdominal adiposity and blood pressure: consistency of their association across developing and developed countries. Int J Obes Relat Metab Disord. 2002;26: 48-57.
• Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA. 1999;282: 1523-1529.
• Field AE, Coakley EH, Must A, Spadano JL, Laird N, Dietz WH, Rimm E, Colditz GA. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med. 2001;161: 1581-1586.
• Perlstein MI, Bissada NF. Influence of obesity and hypertension on the severity of periodontitis in rats. Oral Surg Oral Med Oral Pathol. 1977;43: 707-719.
• Saito T, Shimazaki Y, Sakamoto M. Obesity and periodontitis. N Engl J Med. 1998;339: 482-483.
• Saito T, Shimazaki Y, Koga T, Tsuzuki M, Oshima A. Relationship between upper body obesity and periodontitis. J Dent Res. 2001;80: 1631-1636.
• Saito T, Shimazaki Y, Kiyohara Y, Kato I, Kubo M, Iida M, Lida M, Yamashita Y. Relationship between obesity, glucose tolerance, and periodontal disease in Japanese women: the Hisayama study. J Periodontal Res. 2005;40: 346-353.
• Al-Zahrani MS, Bissada NF, Borawskit EA. Obesity and periodontal disease in young, middle-aged, and older adults. J Periodontol. 2003;74: 610-615.
• Wood N, Johnson RB, Streckfus CF. Comparison of body composition and periodontal disease using nutritional assessment techniques. Third National Health and Nutrition Examination Survey (NHANES III). J Clin Periodontol. 2003;30: 321-327.
• Dalla Vecchia CF, Susin C, Rösing CK, Oppermann RV, Albandar JM. Overweight and obesity as risk indicators for periodontitis in adults. J Periodontol. 2005;76: 1721-1728.
• Genco RJ, Grossi SG, Ho A, Nishimura F, Murayama Y. A proposed model linking inflammation to obesity, diabetes, and periodontal infections. J Periodontol. 2005;76: 2075-2084.
• Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA. 1999;282: 1523-1529.
• Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960-1991. JAMA. 1994;272: 205-211.
• Saw SM, Rajan U. The epidemiology of obesity: a review. Ann Acad Med Singapore. 1997;26: 489-493.
• Meron selassie, BA, Ashish, C. Sinha, MD. The epidemiology and aetiology of obesity: A global challenge. Best Pract Res Clin Anaesthesiol. 2011;25: 1-9
• Saito T, Shimazaki Y, Yamashita Y, Koga T, Tsuzuki M, Sakamoto M. Association between periodontitis and exercise capacity. Periodontal Insights. 1999;62: 9-12.
• Kumanyika SK, Obarzanek E, Stettler N, Bell R, Field AE, Fortmann SP, Franklin BA, Gillman MW, Lewis CE, Poston WC, Stevens J, Hong Y. Population-based prevention of obesity: the need for comprehensive promotion of healthful eating, physical activity, and energy balance: a scientific statement from American Heart Association Council on Epidemiology and Prevention, Interdisciplinary Committee for Prevention (formerly the expert panel on population and prevention science). Circulation. 2008;118(4): 428-64.
• National Heart, Lung and Blood Institute. Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults – the evidence report. Obes Res. 1998;6: 1-78.
• World Health Organization/International Association for the Study of Obesity/International Obesity Takforce. The Asia-Pacific perspective: redefining obesity and its treatment. Available at: http://www.idi. org.au/obesity report.htm.
• Hofbauer KG. Molecular pathways to obesity. Int J Obes Relat Metab Disord. 2002;26 (Suppl. 2): 18-27.
• Jequier E. Leptin signaling, adiposity, and energy balance. Ann N Y Acad Sci. 2002; 967: 379-388.
• Bouchard C & Perusse L. Genetics of obesity. Annual Review of Nutrition. 1993; 13: 337-354.
• Bouchard C, Perusse L, Leblanc C, Tremblay A, Thériault G. Inheritance of the amount and distribution of human body fat. International Journal of Obesity. 1988;12(3): 205-215.
• Agras WS, Hammer LD, McNicholas F, Kraemer HC. Risk factors for childhood overweight: a prospective study from birth to 9.5 years. Journal of Pediatrics. 2004;145(1): 20-25.
• Agras WS, Mascola AJ. Risk factors for childhood overweight. Current Opinion in Pediatrics. 2005;17(5): 648-652.
• Price RA, Cadoret RJ, Stunkard AJ, Troughton E. Genetic contributions to human fatness: an adoption study. American Journal of Psychiatry. 1987;144(8): 1003-1008.
• Maes HH, Neale MC, Eaves LJ. Genetic and environmental factors in relative body weight and human adiposity. Behavior Genetics. 1997;27(4): 325-351.
• Stunkard AJ, Harris JR, Pedersen NL, McClearn GE. The body-mass index of twins who have been reared apart. The New England Journal of Medicine. 1990;322(21): 1483-1487.
• Comuzzie AG, Allison DB. The search for human obesity genes. Science. 1998;280(5368): 1374-1377.
• Farooqi IS, Yeo GS, Keogh JM, Aminian S, Jebb SA, Butler G, Cheetham T, O’Rahilly S. Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency. The Journal of Clinical Investigation. 2000;106(2): 271-279.
• Eckel RH. Obesity: a disease or a physiologic adaptation. In Eckel RH (ed.). Obesity: mechanisms and clinical management. Philadelphia: Lippencott Williams and Wilkins, 2003, pp. 3-30.
• Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ, Sewter CP, Digby JE, Mohammed SN, Hurst JA, Cheetham CH, Earley AR, Barnett AH, Prins JB, O’Rahilly S. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature. 1997;387(6636): 903-908.
• Clement K, Vaisse C, Lahlou N, Cabrol S, Pelloux V, Cassuto D, Gourmelen M, Dina C, Chambaz J, Lacorte JM, Basdevant A, Bougnères P, Lebouc Y, Froguel P, Guy-Grand B. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature. 1998;392(6674): 398-401.
• Ristow M, Muller-Wieland D, Pfeiffer A, Pfeiffer A, Krone W, Kahn CR. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. The New England Journal of Medicine. 1998;339(14): 953-959.
• Jackson RS, Creemers JW, Ohagi S, Raffin-Sanson ML, Sanders L, Montague CT, Hutton JC, O’Rahilly S. Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene. Nature Genetics. 1997;16(3): 303- 306.
• Malik VS, Schulze MB, Hu FB. Intake of sugar-sweetened beverages and weight gain: a systematic review. The American Journal of Clinical Nutrition. 2006;84(2): 274-288.
• Schulze MB, Manson JE, Ludwig DS, Colditz GA, Stampfer MJ, Willett WC, Hu FB. Sugar-sweetened beverages, weight gain, and incidence of type 2 diabetes in young and middle-aged women. Journal of the American Medical Association. 2004;292(8): 927-934.
• Putnam JA, Allshouse JE. Food consumption, prices and expenditures, 1970–1997. Washington, DC: Food and Rural Economic Division, US Department of Agriculture, 1999.
• King GA, Fitzhugh EC, Bassett Jr. DR, McLaughlin JE, Strath SJ, Swartz AM, Thompson DL. Relationship of leisure-time physical activity and occupational activity to the prevalence of obesity. International Journal of Obesity and Related Metabolic Disorders. 2001;25(5): 606- 612.
• Andersen RE, Crespo CJ, Barlett SJ, Cheskin LJ, Pratt M. Relationship of physical activity and television watching with body weight and level of fatness among children. Journal of the American Medical Association. 1998;279(12): 938-942.
• Dumitrescu AL, Kawamura M. Involvement of psychosocial factors in the association of obesity with periodontitis. J Oral Sci. 2010;52: 115-124
• Abelson P, Kennedy D. The obesity epidemic. Science. 2004;304: 1413.
• Haslam D, James P. Obesity. Lancet. 2005;366: 1197-1209.
• Prentice AM. The emerging epidemic of obesity in developing countries. Int J Epidemiol. 2006;35(1): 93-99.
• Nishida C, Mucavele P. Monitoring the rapidly emerging public health problem of overweight and obesity: The WHO Global Database on Body Mass Index. SCN News. 2005;(29): 5-12.
• Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 2004;92: 347-355.
• Ritchıe, CS. Obesity and periodontal diseases. Periodontology. 2000 2007;44: 154-163
• Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature.1994;372: 425-432.
• Kennedy GC. The role of depot fat in the hypothalamic control of food intake in the rat. Proc R Soc Lond B Biol Sci. 1953;140: 578-596.
• Friedman JM. Leptin, leptin receptors, and the control of body weight. Nutr Rev. 1998;56: 38-46; discussion 54-75.
• Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes IA, McCamish MA, O’Rahilly S. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999;341: 879-884.
• Margetic S, Gazzola C, Pegg GG, Hill RA. Leptin: a review of its peripheral actions and interactions. Int J Obes Relat Metab Disord. 2002;26: 1407-1433.
• Thomas T, Gori F, Khosla S, Jensen MD, Burguera B, Riggs BL. Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation of adipocytes. Endocrinology. 1999;140: 1630-1638.
• Ducy P, Schinke T, Karsenty G. The osteoblast: a sophisticated fibroblast under central surveillance. Science. 2000;289: 1501-1504.
• Cornish J, Callon KE, Bava U, Lin C, Naot D, Hill BL, Grey AB, Broom N, Myers DE, Nicholson GC, Reid IR. Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo. J Endocrinol.
• Reseland JE, Syversen U, Bakke I, Qvigstad G, Eide LG, Hjertner O, Hjertner O, Gordeladze JO, Drevon CA. Leptin is expressed in and secreted from primary cultures of human osteoblasts and promotes bone mineralization. J Bone Miner Res. 2001;16: 1426-1433.
• Thomas T. Leptin: a potential mediator for protective effects of fat mass on bone tissue. Joint Bone Spine. 2003;70: 18-21.
• Thomas T, Burguera B. Is leptin the link between fat and bone mass? J Bone Miner Res. 2002;17: 1563-1569.
• Otero M, Lago R, Lago F, Casanueva FF, Dieguez C, Gomez-Reino JJ, Gualillo O. Leptin, from fat to inflammation: old questions and new insights. FEBS Lett 2005; 579:295-301.
• Grunfeld C, Zhao C, Fuller J, Pollack A, Moser A, Friedman J, Feingold KR. Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. J Clin Invest. 1996;97: 2152-2157.
• Faggioni R, Fantuzzi G, Fuller J, Dinarello CA, Feingold K, Grunfeld C. Il-1 beta mediates leptin induction during inflammation. Am J Physiol. 1998;274: 204-208.
• Johnson RB, Serio FG. Leptin within healthy and diseased human gingiva. J Periodontol. 2001;72: 1254-1257.
• Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab. 2002;13: 84-89.
• Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone? Diabetes Care 2003; 26: 2442- 2450.
• Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, Hotta K, Nishida M, Takahashi M, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y. Adiponectin, an adipocyte- derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation. 2000;102:1296- 1301.
• Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, Ishigami M, Kuriyama H, Kishida K, Nishizawa H, Hotta K, Muraguchi M, Ohmoto Y, Yamashita S, Funahashi T, Matsuzawa Y. Adipocyte- derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte- derived macrophages. Circulation. 2001;103: 1057-1063.
• Arita Y, Kihara S, Ouchi N, Maeda K, Kuriyama H, Okamoto Y, Kumada M, Hotta K, Nishida M, Takahashi M, Nakamura T, Shimomura I, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Adipocyte- derived plasma protein adiponectin acts as a platelet derived growth factor-BB-binding protein and regulates growth factorin duced common postreceptor signal in vascular smooth muscle cell. Circulation. 2002;105: 2893-2898.
• Kubota N, Terauchi Y, Yamauchi T, Kubota T, Moroi M, Matsui J, Eto K, Yamashita T, Kamon J, Satoh H, Yano W, Froguel P, Nagai R, Kimura S, Kadowaki T,Noda T. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem. 2002;277: 25863-25866.
• Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte- secreted protein Acrp30 enhances hepatic insulin action. Nat Med. 2001;7: 947-953.
• Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001;7: 941- 946.
• Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA, Knowler WC, Krakoff J. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet. 2002;360: 57-58.
• Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, Furuyama N, Kondo H, Takahashi M, Arita Y, Komuro R, Ouchi N, Kihara S, Tochino Y, Okutomi K, Horie M, Takeda S, Aoyama T, Funahashi T, Matsuzawa Y. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med. 2002;8: 731-737.
• Spranger J, Kroke A, Mohlig M, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF. Adiponectin and protection against type 2 diabetes mellitus. Lancet. 2003;361(9353): 226-228.
• Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. J Am Med Assoc. 2004;291: 1730-1737.
• Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. Nature. 2001;409: 307-312.
• Rajala MW, Lin Y, Ranalletta M, Yang XM, Qian H, Gingerich R, Barzilai N, Scherer PE. Cell type-specific expression and coregulation of murine resistin and resistin-like molecule-alpha in adipose tissue. Mol Endocrinol. 2002;16: 1920-1930.
• Nagaev I, Smith U. Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem Biophys Res Commun. 2001;285: 561-564.
• Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV, O’Rahilly S. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes. 2001;50: 2199-2202.
• Banerjee RR, Lazar MA. Rezistin: Molecular history and prognosis. J Mol Med. 2003;81: 218-226.
• Verma S, Li SH, Wang CH, Fedak PW, Li RK, Weisel RD, Mickle DA. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation. 2003;108: 736-740.
• Kawanami D, Maemura K, Takeda N, Harada T, Nojiri T, Imai Y, Manabe I, Utsunomiya K, Nagai R. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun. 2004;314: 415-419.
• Holcomb IN, Kabakoff RC, Chan B, Baker TW, Gurney A, Henzel W, Nelson C, Lowman HB, Wright BD, Skelton NJ, Frantz GD, Tumas DB, Peale FV Jr, Shelton DL, Hébert CC. FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. EMBO J. 2000;19: 4046-4055.
• Gomez-Ambrosi J, Fruhbeck G. Do resistin and resistin-like molecules also link obesity to inflammatory diseases? Ann Intern Med. 2001;135: 306-307.
• Pischon T, Bamberger CM, Kratzsch J, Zyriax BC, Algenstaedt P, Boeing H, Windler E. Association of plasma resistin levels with coronary heart disease in women. Obes Res. 2005;13: 1764-1771.
• Burnett MS, Devaney JM, Adenika RJ, Lindsay R, Howard BV. Cross- sectional associations of resistin, coronary heart disease and insulin resistance. J Clin Endocrinol Metab. 2006;91: 64-68.
• Tsigos C, Kyrou I, Chala E, Tsapogas P, Stavridis JC, Raptis SA, Katsilambros N. Circulating tumor necrosis factor alpha concentrations are higher in abdominal versus peripheral obesity. Metabolism. 1999;48: 1332-1335.
• Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005; 96: 939-949.
• Hotamisligil, G, Shargill, N, Spiegelman, BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259: 87-91.
• Ruan H, Miles PDG, Ladd CM, Ross K., Golub TR, Olefsky JM, Lodish HF. Profiling gene transcription in vivo reveals adipose tissue as an immediate target of tumor necrosis factor-{alpha}: implications for insulin resistance. Diabetes. 2002;51: 3176-3188.
• Niemann-Jonsson A, Dimayuga P, Jovinge S, Calara F, Ares MPS, Fredrikson GN, Nilsson J. Accumulation of LDL in rat arteries is associated with activation of tumor necrosis factor-a expression. Arterioscler Thromb Vasc Biol. 2000;20: 2205-2211.
• Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald W. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation. 2000;101: 2149-2153.
• Simons PJ, van den Pangaart PS, van Roomen CP, Aerts JM, Boon L. Cytokine-mediated modulation of leptin and adiponectin secretion during in vitro adipogenesis: evidence that tumor necrosis factor- alpha- and interleukin-1beta treated human preadipocytes are potent leptin producers. Cytokine. 2005;32: 94-103.
• Lazar MA. How obesity causes diabetes: not a tall tale. Science. 2005;307: 373-375.
• Mohamed-Ali, V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klei, S, Coppack SW. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J. Clin. Endocrinol. Metab. 1997;82: 4196-4200.
• Ridker PM, Willerson JT. Inflammation as a cardiovascular risk factor. Circulation. 2004;109(Suppl. 2): 2-10.
• Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101: 1767-1772.
• Mertens I, Van Gaal LF. Obesity, haemostasis and the fibrinolytic system. Obes Rev. 2002;3: 85-101.
• Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology. 2004;145: 2273-2282.
• Mavri A, Alessi MC, Bastelica D, Geel-Georgelin O, Fina F, Sentocnik JT, Stegnar M, Juhan-Vague I. Subcutaneous abdominal, but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-1) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss. Diabetologia. 2001;44: 2025-2031.
• DeTaeye B, Smith LH, Vaughan DE. Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease. Curr Opin Pharmacol. 2005;5: 149-154.
• Juhan-Vague I, Alessi MC, Mavri A, Morange PE. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost. 2003;1: 1575-1579.
• Boustany CM, Bharadwaj K, Daugherty A, Brown DR, Randall DC, Cassis LA. Activation of the systemic and adipose renin-angiotensin system in rats with diet-induced obesity and hypertension. Am J Physiol Regul Integr CompPhysiol. 2004;287: 943-949.
• Engeli S, Schling P, Gorzelniak K, Boschmann M, Janke J, Ailhaud G, Teboul M, Massie´ra F, Sharma AM. The adipose-tissue renin– angiotensin–aldosterone system: role in the metabolic syndrome? Int J Biochem Cell Biol 2003; 35: 807-825.
• Miyazawa-Hoshimoto S, Takahashi K, Bujo H, Hashimoto N, Saito Y. Elevated serum vascular endothelial growth factor is associated with visceral fat accumulation in human obese subjects. Diabetologia. 2003;46: 1483-1488.
• Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286: 327-334.
• Collazo-clavell ML. Safe and effective management of the obese patient. Mayo Clin Proc. 1999;74: 1255.
• Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. J Am Med Assoc. 1999;282: 1523-1529.
• Dyer AR, Elliott P, Shipley M. Body mass index versus height and weight in relation to blood pressure. Finding for the 10,079 persons in the INTERSALT Study. Am J Epidemiol. 1990;131: 589-596.
• Huang, Z, Willett WE, Manson JE, Rosner B, Stampfer MJ, Speizer FE. Body weight, weight change, and risk for hypertension in women. Ann Intern Med. 1998;128: 81-88.
• Appel LJ, Moore TJ, Obarzanek R, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM, Lin PH, Karanja N. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med. 1997;336: 1117- 1124.
• Raben A, Vasilaras TH, Moller AC, Astrup A. Sucrose compared with artificial sweeteners: different effects on ad libitum food intake and body weight after 10 wk of supplementation in overweight subjects. Am J Clin Nutr. 2002;76: 721-729.
• Avenell A, Broom J, Brown TJ, Poobalan A, Aucott L, Stearns SC, Smith WC, Jung RT, Campbell MK, Grant AM. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess. 2004;8: 1-182.
• Kolanowski J. Obesity and hypertension: from pathophysiology to treatment. Int J Obes Relat Metab Disord. 1999;23(Suppl 1): 42-46.
• Ritchie, CS. Obesity and periodontal diseases. Periodontology 2000, 2007; 44: 154-163.
• Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26 year follow- up of participants in the Framingham Heart Study. Circulation.
• Wilson PW, D’Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med. 2002;162: 1867-1872.
• Ni Mhurchu C, Rodgers A, Pan WH, Gu DF, Woodward M; Asia Pacific Cohort Studies Collaboration. Body mass index and cardiovascular disease in the Asia-Pacific Region: an overview of 33 cohorts involving 310,000 participants. Int J Epidemiol. 2004:33: 751-758.
• Kenchaiah S, Gaziano JM, Vasan RS. Impact of obesity on the risk of heart failure and survival after the onset of heart failure. Med Clin North Am. 2004;88: 1272-1294.
• Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, et al. Obesity and the risk of heart failure. N Engl J Med. 2002;347: 305-313.
• Gortmaker SL, Must A, Perrin JM, Sobol AM, Dietz WH. Social and economic consequences of overweight in adolescence and young adulthood. N Engl J Med. 1993;329: 1008-1012.
• Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005;365(9467): 1333-1346.
• Fontaine KR, Cheskin LJ, Barofsky I. Health-related quality of life in obese persons seeking treatment. J Fam Pract. 1996;43: 265.
• Carpenter KM, Hasin DS, Allison DB, Faith MS. Relationships between obesity and DSM-IV major depressive disorder, suicide ideation, and suicide attempts: results from a general population study. Am J Public Health. 2000;90: 251.
• Felson DT, Anderson JJ, Naimark A, Walker AM, Meenan RF. Obesity and knee osteoarthritis. The Framingham Study. Ann Intern Med. 1988;109: 18-24.
• Bray GA. Contemporary diagnosis and management of obesity and the metabolic syndrome. 3rd ed. Newton, PA: Handbooks in health care 2003.
• Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath Jr CW. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med. 1999;341: 1097-1105.
• Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. J Am Med Assoc. 2004;291: 1238- 1245.
• Flegal KM, Graubard BI, Williamson DF, Gail MH. Excess deaths associated with underweight, overweight and obesity. J Am Med Assoc. 2005;293:1861-1867.
• Curtis JP, Selter JG, Wang Y, Rathore SS, Jovin IS, Jadbabaie F, Kosiborod M, Portnay EL, Sokol SI, Bader F, Krumholz HM. The obesity paradox: body mass index and outcomes in patients with heart failure. Arch Intern Med. 2005;165: 55-61.
• Troiano RP, Frongillo EA Jr, Sobal J, Levitsky DA. The relationship between body weight and mortality: a quantitative analysis of combined information from existing studies. Int J Obes Relat Metab Disord. 1996;20: 63-75.
• Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr. Bodymass index and mortality in a prospective cohort of U.S. adults. N Engl J Med. 1999;341: 1097-1105.
• Freedman DM, Ron E, Ballard-Barbash R, Doody MM, Linet MS. Body mass index and all-cause mortality in a nationwide US cohort. Int J Obes. 2006;30: 822-829.
• Field AE, Coakley EH, Must A. Impact of overweight on the risk of developing common chronic diseases during a 10- year period. Arch Int Med. 200;161: 1581-1586.
• Lundin M, Yucel-Lindberg T, Dahllof G, Marcus C, Modeer T. Correlation between TNF-a in gingival fluid and body mass index in obese subjects. Acta Odontol Scand. 2004;62: 273-277.
• Avenell A, Broom J, Brown TJ, Poobalan A, Aucott L, Stearns SC, Smith WC, Jung RT, Campbell MK, Grant AM. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess. 2004;8: 1-182.
• Bouchard C, Tremblay A. Genetic effects in human energy expenditure components. Int J Obes. 1990;14(Suppl. 1): 49-58.
• Ritchie CS, Kinane DF. Nutrition, inflammation and periodontal disease. Nutr. 2003;19: 475-476.
• N. Pischon, N. Heng, J.-P. Bernimoulin, B.-M. Kleber, S.N. Willich and T. Pischon. Obesity, Inflammation, and Periodontal Disease. J Dent Res. 2007;86: 400.